This article refers to aspirin enhancing the immune response of T cells to metastatic cells. Since the main problem of cancers is related to not detecting them until they have already spread, this limits the potential benefit of aspirin to patients who have already had cancer, in order to prevent recurrence or to people with "early cancer", as mentioned in the article abstract.

Another issue with aspirin is that it increases the rate of bleeding in general, and in the GI tract in particular, which is a significant side effect and any potential benefit would have to be higher than that.

In other words, I'll hold my breath, at least until we have more data.